Viking Therapeutics, Inc. (VKTX) earnings
VKTX earnings moved a median of +1.05% by the close. Quarterly and annual VKTX reports and results, each read against the price at its own news timestamp. Back to the VKTX overview →
30 measured VKTX earnings events.
Where these VKTX earnings landedvs 30 measured VKTX earnings reactions
| Middle 50% of VKTX earnings reactions | -2.14% to +8.31% |
|---|---|
| Median reaction (to close) | +1.05% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 VKTX earnings events with a measured close landed between -2.14% and +8.31%; 53% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Viking Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -4.95% | -1.22% | |
| Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -4.95% | -1.22% | |
| Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 | Press release | -0.76% | -3.44% | |
| Form 10-Q Viking Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -2.71% | +2.30% | |
| Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | -2.71% | +2.30% | |
| Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026 | Press release | -0.29% | -4.09% | |
| Form 10-K Viking Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -3.47% | -10.32% | |
| Form 10-Q Viking Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.13% | -4.29% | |
| Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -1.13% | -4.29% | |
| Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025 | Press release | -0.13% | -2.31% | |
| Form 10-Q Viking Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +6.95% | +6.35% | |
| Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | +6.95% | +6.35% | |
| Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 | Press release | +1.46% | +0.22% | |
| Form 10-Q Viking Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.36% | -0.60% | |
| Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -2.68% | -1.65% | |
| Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 | Press release | +2.68% | +8.62% | |
| Form 10-K Viking Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.17% | +1.88% | |
| Form 10-Q Viking Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.21% | +11.36% | |
| Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -2.21% | +11.36% | |
| Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024 | Press release | -0.39% | -1.94% | |
| Form 10-Q Viking Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.79% | +9.11% | |
| Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -0.79% | +9.11% | |
| Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 | Press release | -1.53% | -1.92% | |
| Form 10-Q Viking Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.09% | +9.30% | |
| Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.09% | +9.30% | |
| Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 | Press release | -0.47% | -2.21% | |
| Form 10-K Viking Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +5.24% | +12.19% | |
| Form 10-Q Viking Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.22% | +7.39% | |
| Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | -0.22% | +7.39% | |
| Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023 | Press release | -2.03% | -2.51% |
Keep exploring
More VKTX: analyst actions → · SEC filings → · VKTX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Pulse Biosciences, Inc (PLSE) | 320 | +0.18% | 55% |
| Voyager Therapeutics, Inc. (VYGR) | 320 | -0.12% | 42% |
| Aptevo Therapeutics Inc. (APVO) | 318 | -0.89% | 34% |
| MATEON THERAPEUTICS (MATN) | 318 | 0.00% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.